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ABSTRACT 
Objective: To evaluate stability of drug by force degradation studies and to develop validated RP-HPLC method for quantitative estimation of 
fluvoxamine maleate in pharmaceutical dosage form. 
Methods: The optimized chromatographic conditions utilizes reversed-phase C18 Hyperchrome ODS column (250X4.6 mm, 5µ), mobile phase 
comprised of Methanol and Phosphate buffer (pH-2.5) in the ratio of 70:30 v/v, flow rate of 1 ml/min at ambient temperature and UV detection at 
250 nm.  
Results: In the proposed method the retention time of fluvoxamine was found to be 5.94 min. The linearity of the proposed method was tested in 
the range of 10-50 μg/ml and correlation coefficient was found to be 0.998. The accuracy of the proposed method was carried out by standard 
addition method and found to be 99.62%. The % RSD of precision study was calculated as 0.69. The standard and marketed formulation exposed to 
hydrolytic and oxidative stress conditions indicates significant degradation with good resolution between the peaks corresponds to degradation 
products and analyte. The proposed force degradation study shows that fluvoxamine is labile molecule to acid, alkali, neutral and oxidative 
conditions and also susceptible to degradation when exposed to UV light, and humidity conditions while it was stable under dry heat (50 °C). 
Conclusion: The proposed validated HPLC method for the quantitative estimation of fluvoxamine maleate in tablet dosage form is accurate, precise, 
economic, and robust. The developed stability indicating method can be recommended for analysis of drug and its degradation products in stability 
samples. 
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INTRODUCTION 
Chemically Fluvoxamine maleate (FLV), is (E)-5-methoxy-1-[4-
(trifluoromethyl) Phenyl] pentan-1-one O-2-aminoethyl oxime 
maleate (Fig.1), an antidepressant which functions as a selective 
serotonin reuptake inhibitor (SSRI). It is also prescribed to 
treat major depressive disorder (MDD) and anxiety disorders, such 
as panic disorder and post-traumatic stress disorder (PTSD). It has 
molecular weight 434.4 and soluble in ethanol, methanol and 
chloroform [1]. 
Literature survey reveals that RP-HPLC [2-5] methods are reported 
for the estimation of Fluvoxamine in plasma as the single dosage 
form or in combination with other drugs. Also some RP-HPLC [6-8] 
methods reported for analysis of said drug in tablets. A detailed 
literature also indicates UV-Spectophotometric [9], Polarographic 
[10], HPTLC [11] and Capillary GC [12] methods are reported for 
estimation of Fluvoxamine. An attempt was made to develop and 
validate totally new, precise, accurate, economic, isocratic RP-HPLC 
method for the quantitative estimation of Fluvoxamine in presence 
of its degradation products as per ICH guidelines. This manuscript 
gives the report for the application of specific stability indicating 
with degradation kinetics and RP-HPLC method in estimation of 
drug from its pharmaceutical dosage form. 
 
 
Fig. 1: Structure of Fluvoxamine maleate 
MATERIALS AND METHODS 
Chemicals and reagents 
Analytical pure sample of Fluvoxamine maleate (Purity 99.27% 
w/w) was obtained as gift samples from Zydus Cadilla Healthcare 
Ltd., Ahmedabad. Marketed formulation containing 50 mg of 
Fluvoxamine maleate was purchased from local market. HPLC grade 
Methanol, Acetonitrile, and Potassium dihydrogen orthophosphate, 
Hydrochloric acid, Sodium hydroxide, Hydrogen peroxide of GR 
grade were used during the experimentation. 
Instrumentation and chromatographic conditions 
HPLC analysis was performed on Shimadzu HPLC series 1100 
chromatograph equipped with binary pump LC-10ADvp, UV-Visible 
detector with manual injector 7725 I (Rheodyne) with 20 µl loop 
and a reserved phase 5µ Hyperchrome ODS C18 column (250x4.6 
mm) with pore size of 100 Ao 
The column was maintained at ambient temperature and injection 
volume of 20 μl was used. The mobile phase was filtered through 
0.45 μm membrane filter prior to use. 
was used for chromatographic studies. 
Chromatographic separation was achieved using a mobile phase 
containing Methanol and Phosphate buffer (pH-2.5) in the ratio of 
70:30 v/v, at a flow rate of 1 ml/min and the eluent was monitored 
using UV detector at a wavelength 250 nm.  
Preparation of buffer (pH-2.5) 
In 1000 ml volumetric flask, 10g potassium dihydrogen 
orthophosphate was dissolved in sufficient amount of double 
distilled water and pH 2.5 adjusted with 0.1NHCl and volume was 
made up to the mark with double distilled water.  
Preparation of working standard solution 
A stock solution of FLV was prepared in methanol having the 
concentration of 1 mg/ml. A 1.0 ml portion of this solution was 
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further diluted with mobile phase to get the final concentration 20 
μg/ml of FLV.  
System suitability parameters 
The system suitability test is an integral part of chromatographic 
methods and used to verify that the reproducibility of the 
chromatographic system is adequate for the analysis to be 
performed. A RP-HPLC method was developed keeping in mind the 
system suitability parameters i.e. retention time, asymmetry, 
theoretical plates and percent Relative standard deviation of six 
injections were evaluated.  
Specificity 
Specificity is the ability to assess unequivocally the analyte in the 
presence of components that may be expected to be present. The 
specificity of the method was performed by injecting mix standard 
solution of FLV, marketed formulation and blank.  
Calibration curve 
Aliquots of the standard solution were diluted in the range 1.0 ml to 
5.0 ml in a series of 10 ml volumetric flasks with the mobile phase to 
obtain the concentration range 10 μg/ml to 50 μg/ml for FLV. 
Calibration curve was constructed by plotting an area under curve 
against concentration. 
Force degradation study 
To evaluate intrinsic stability, FLV was subjected to force 
degradation as per International Community on Hormonization 
(ICH) guidelines to get an idea of how drug substance or product 
degrades, degenerate and behaves under changing condition, which 
helps in developing stability indicating method of analysis. This 
study was performed on standard FLV and its marketed formulation 
viz: Solution state degradation and Solid state degradation. 
Solution state degradation 
At concentration of 50 μg/ml for FLV, degradation studies in 
solution was carried out at 80 °C in an oven for 90 min. Standard and 
marketed formulation was degraded in acidic and alkaline medium 
using 0.1N HCl, 0.1N NaOH, neutral hydrolysis in distill water and 
Oxidative degradation in 3% H2O2
Solid state analysis 
. Analysis of exposed standard 
was done after 90 min while sample solutions were analyzed at an 
interval of 15, 30, 45, 60 and 90 min. 
Solid samples of standard and marketed formulation exposed to 
Humidity studies (40 °C/75% RH), Photo stability studies (UV light) 
and Thermal studies (Dry Heat) over a period of 15 days. The 
samples were analysed on 1st, 4th, 7th and 15th
After specified time intervals, the stress solutions and solid stressed 
samples were allowed to cool at room temperature and diluted with 
methanol. The solution was filtered with whatmann filter paper 
(No.41). Further dilution with mobile phase of sample and standard 
solution were carried out. After equilibration of column with mobile 
phase 20 μL solution was injected to column under proposed 
conditions and chromatographed separately, AUC was noted and % 
un-degraded drug was calculated for each solution using  
 day. Solid state 
analysis was performed at a drug concentration of 20 μg/ml of FLV. 
The study was performed for observing % un-degraded of the active 
ingredient and study of pattern of UV spectra of an exposed sample. 
Formula for sample 
 
 
Formula for standard  
 
 
Where, Au-area of unknown, As (expose)-area of exposed standard, 
As (unexposed)-area of unexposed standard, Wt. std (unexposed)-
weight of standard taken, Wt. std (exposed)-weight of exposed 
standard taken, Wtab-weight of tablet powder taken, L. C.-label 
claim of drug  
Application of proposed method to marketed formulation 
(precision) 
The proposed method was applied to the determination of FLV in 
commercial dosage form, Fluvoxin tablets. An accurately weighed 
quantity of tablet powder equivalent to 10 mg of FLV was 
transferred to 10 ml volumetric flasks and volume was made up to 
the mark with methanol. The content was sonicated for 15 min and 
filtered through whatmann filter paper. A 1.0 ml portion of filtrate 
was diluted to 10 ml with the mobile phase. After that 2.0 ml portion 
of this solution were further diluted to 10 ml with the mobile phase.  
After equilibration of the column with the mobile phase 20 µl 
volume of the final diluted solutions were injected in the system. 
Analysis of such six replicate of final diluted solution was carried out 
using optimized chromatographic conditions. AUC noted and % 
labeled claim was calculated.  
Validation of proposed method 
The developed method was validated as per the ICH guidelines with 
respect to various parameters such as linearity, accuracy, precision, 
and robustness, ruggedness, limit of detection and limit of 
quantification  
Accuracy (% recovery) 
Accuracy was determined by means of recovery experiments, by the 
determination of % mean recovery of sample at five different levels 
(90%, 95%, 100%, 105%, and 110%). The amount of each drug 
contributed by the preanalysed tablet powder was deducted from 
total amount of respective drug estimated and resultant quantities 
were assured to be recovered from the pure drug added. 
Intermediate precision 
For intra-day, sample solution (20µg/ml) was prepared as per the 
procedure described under marketed formulation and analyzed at 
intervals of 0thh, 2h, 6h and 8h and same solution analyzed at 
intervals of 1st, 3rd and 5th
Analyst to analyst variation 
day.  
The sample solution was prepared by two different analysts in same 
manner to that of marketed formulation. Then sample solutions 
were analyzed using the proposed method. 
Linearity and range 
Accurately weighed quantities of tablet powder equivalent to 80, 90, 
100, 110 and 120 % of label claim were taken separately and 
dilutions were made as described under marketed formulation. 
After equilibration of the column with mobile phase 20 µl volume of 
the final diluted solutions were injected in the system separately and 
chromatograms were recorded. Linearity curve was constructed by 
plotting the concentration level of drug verses corresponding peak 
area. 
Sensitivity 
The limit of detection (LOD) is defined as the lowest concentration 
of an analyte that can reliably be differentiated from background 
levels. Limit of quantification (LOQ) of an individual analytical 
procedure is the lowest amount of analyte that can be quantitatively 
determined with suitable precision and accuracy. The LOD and LOQ 
were calculated based on the equation:  
LOD = 3.3 × S/B and LOQ = 10 × S/B 
Where, S is SD of peak areas of the drugs taken as a measure of noise 
and B is the slope of the corresponding calibration curve. The 
sensitivity of detection of FLV by use of the proposed method was 
determined in terms of limit of detection (LOD) and limit of 
quantitation (LOQ). 
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Robustness  
Robustness of the proposed method was determined by small 
deliberate changes in the composition of mobile phase ratio (±10%) 
of mobile phase, pH (±0.2) and detection wavelength (±5 nm). 
RESULTS AND DISCUSSION 
Various mobile phases were tried by permutation and combinations 
and also by varying flow rate, column temperature and types of 
buffers with varying pH and solvents. The prepared different mobile 
phases were filtered through 0.45μm membrane filter paper prior to 
use.  
The mobile phase composition at a ratio of 70:30 (v/v) of methanol 
and phosphate buffer pH 2.5 was found to be most suitable to obtain 
peak of FLV at 5.94 min is well defined and free, from tailing. 
System suitability parameter 
The optimized method developed resulted in the elution of FLV at 
5.94 min. Fig. 2 represents the typical chromatogram of standard 
FLV. System suitability parameters were evaluated for six replicate 
injections of standard at 10 µg/ml. Results of system suitability 
parameters recorded in table 1. 
 
 
Fig. 2: Typical chromatogram of standard FLV
 
Table 1: System suitability parameters 
Wt. of Std. taken (g) Mean area (µV) ±SD Retention time Asymmetry Theoretical plates 
0.010 601122.33 1927.56 5.939 1.05 8874 
*Each observation is mean of six observations 
 
Specificity 
Chromatograms of standard FLV (fig. 2) and sample (fig. 3) reveal 
that the peak obtained in the standard solution and the sample 
solution at working concentration are only because of drug as blank 
has no peak at the rentention time of FLV. No excipents were found 
to elute at the retention times of the said drugs in the sample 
solution shows developed method is said to be specific. 
 
Fig. 3: Typical chromatogram of FLV from tablet formulation 
 
Calibration curve 
Calibration curve plot (fig. 4) of an area under curve against 
concentration shows that FLV was found to be linear over the range 
of 10-50 μg/ml with correlation coefficient 0.998. 
 
 
Fig. 4: Linearity curve of FLV 
Force degradation studies 
Chromatograms of base, acid, neutral and peroxide stressed 
marketed samples (fig. 5a-5d) and of Std. (fig. 6a-6d) are shown in 
respectively.  
Similarly chromatograms of solid state analysis of the standard and 
sample are depicted in (fig. 7a-7c) and (fig. 8a-8c) respectively. The 
results of forced degradation study are given in table 2. 
 
 
Fig. 5a: Chromatogram of base stressed sample 
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Fig. 5c: Chromatogram of water stressed sample 
 
 
Fig. 5d: Chromatogram of peroxide stressed sample 
 
 
Fig. 6a: Chromatogram of base stressed standard 
 
Fig. 6b: Chromatogram of acid stressed standard 
 
 
Fig. 6c: Chromatogram of distill water stressed standard 
 
 
Fig. 6d: Chromatogram of peroxide stressed standard 
 
  
Fig. 7a: Chromatogram of exposed Std. to Humidity Fig. 8a: Chromatogram of exposed sample to Humidity 
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Fig. 7b: Chromatogram of exposed Std. to UV light 
 
Fig. 8b: Chromatogram of exposed sample to UV light 
 
  
Fig. 7c: Chromatogram of exposed Std. to Heat Fig. 8c: Chromatogram of exposed sample to Heat 
 
Table 2: Force degradation study 
Degradation parameters Interval % Drug un-degraded  
Exposed Std. Exposed MF 
FLV 
Solution state analysis 
Acid degradation (0.1 M HCl) At 80 °C, 
90 min 
76.77 55.21 
Base degradation (0.1 M NaOH) 88.97 84.26 
Peroxide degradation (3% H2O2 86.75 ) 80.25 
Distill water degradation 79.93 77.75 
Solid state analysis 
Humidity studies (40 °C/75% RH) 15Days 
*7day 
83.94 84.37 
Photo stability studies (UV light) 86.45* 7.00* 
Thermal studies (50 °C) 94.41 90.63 
 
FLV was found to be labile to alkaline, neutral and oxidative condition 
as degradation was found to be around 20% in exposed standard and 
in sample while it was found to be 40% to acidic hydrolysis indicating 
extremely labile nature. Two additional degradants peaks [Deg1 (RRT-
0.89); Deg2 (RRT-1.07)] were seen in chromatogram of sample under 
alkaline hydrolysis. One additional degradant peak [Deg1 (RRT-0.89)] 
was seen in chromatogram of sample under acidic hydrolysis. Two 
additional degradants peaks [Deg1 (RRT-0.74); Deg2 (RRT-0.99)] 
were seen in chromatogram of sample under neutral hydrolysis. One 
additional degradant peak [Deg1 (RRT-0.91)] was seen in 
chromatogram of sample under oxidative hydrolysis. The RRT of 
impurities reported in BP 2009[13] does not match with the 
degradant RRTs leading to formation of unknown impurities in sample 
under stress. Sample and standard FLV shows sufficient degradation 
when exposed to humidity, heat and light. Almost 93% degradation of 
sample on 7 day was seen under UV exposure (ICH Recommended) 
with additional peak seen in the chromatogram. There was complete 
separation of degradation peaks and analyte peaks, which 
demonstrate the specificity of assay method for estimation of FLV in 
the presence of its degradation products; it can be employed as a 
stability indicating one and can be used to assess the stability of FLV in 
the bulk drug and in pharmaceutical dosage forms 
Kinetics of solution state degradation studies 
The kinetics of degraded samples was evaluated for all the 
hydrolytic conditions. The plot of regression coefficient (r) obtained 
and the best fit observed indicates the order of degradation reaction. 
a) Values of concentration against time (zero-order kinetics) 
b) Log of concentration verses time (first-order kinetics) 
c) Reciprocal of concentration verses time (second-order kinetics) 
The observation and results of kinetics of degradation so recorded 
as shown in table 3. 
Gupta et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 6, 196-202 
201 
Table 3: Kinetics of degradation studies 
Degradation Study Value of ‘r’ Order of reaction 
FLV 
Acid Hydrolysis 0.978 Second 
Alkali Hydrolysis 0.984 Zero 
Oxidation 0.977 Zero 
Neutral Hydrolysis 0.832 Second 
Precision (% Assay) 
Precision is a measure of the reproducibility of the whole analytical 
method under normal operating circumstances. The precision was 
expressed as the relative standard deviation (RSD). The result 
shown in table 4 indicates that the method is selective for the assay 
of FLV without interference from the excipients used in these 
tablets. A low value of standard deviation (0.69) is indicative of high 
precision of the proposed method. 
 




AUC of Standard 
(µV) 
AUC of Sample 
(µV) 




51.72 1202705 99.23 
50.92 1180403 98.92 
52.10 1220698 99.98 
51.98 1196205 98.20 
50.43 1182163 100.03 
 Mean 99.27 
±SD 0.68 
% RSD 0.69 
*fluvoxamine mealate estimated as fluvoxamine 
 
Intermediate precision and Analyst variations 
% RSD value indicates the acceptable reproducibility and thereby 
the precision of the system. Summary of results are shown in table 5. 
 
Table 5: Intermediate precision and Analyst variations 




Intraday 99.75 0.45 0.45 
Interday 98.72 0.83 0.85 
Analyst to 
Analyst 
99.82 0.74 0.75 
 
Accuracy 
The % recovery was found within range, 98.34%-101.36% for FLV 
which indicates high accuracy of the method. Percent mean recovery 
was calculated as shown in table 6. The accepted limits of recovery 
98%-102% and all observed data are within the required range 
which indicates good recovery values and hence the accuracy of the 
method developed.  
 
Table 6: Recovery study 
Wt. of tablet 
powder (mg) 
Amt. of Std. 
FLV added 
(mg) 






25.84 3.98 3.97 99.74 
25.40 4.40 4.46 101.36 
25.88 4.98 4.96 99.60 
26.03 5.51 5.46 99.09 
26.10 6.05 5.95 98.34 







Linearity and range 
The correlation coefficient of FLV was found to be 0.999 indicates 
excellent correlation between peak area and concentration level of 
drug (fig. 9). 
 
Fig. 9: Linearity and range plot of FLV 
 
Sensitivity 
The limit of detection (LOD) and limit of quantitation (LOQ) was 
found to be 0.109 µg/ml and 0.332µg/ml respectively. The results 
show very good sensitivity of the developed method.  
Robustness 
The content of the drug was not adversely affected by these changes 
as evident from the low value of mean RSD (1.55) indicating that the 
method was rugged and robust (table 7). 
 
Table 7: Robustness data 
Parameters RT Asymmetry Theoretical plate 
Mean 5.907 1.05 8743.57 
RSD 1.74 0.93 1.98 
 Mean RSD 1.55 
 
CONCLUSION 
The proposed HPLC method is stability indicating one, cost effective 
and less time consuming. The low percent RSD values of validation 
parameters indicates the method is accurate, precise and robust. 
Hence the proposed method is rapid, accurate and robust. Moreover 
the degraded peaks were well resolved from analyte peaks. So the 
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developed method may be used for analysis of stability samples of 
FLV in quality control laboratory. 
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